search
Back to results

Telerehabilitation in Multiple Sclerosis

Primary Purpose

Multiple Sclerosis

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
VRRS Khymeia
Usual care program
VRRS Khymeia plus active tDCS
VRRS Khymeia plus placebo tDCS
Sponsored by
Fondazione Don Carlo Gnocchi Onlus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Sclerosis focused on measuring Telerehabilitation, Virtual reality, Quality of life, transcranial Direct Current Stimulation

Eligibility Criteria

25 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Confirmed diagnosis of Multiple Sclerosis (RR and SP) based on McDonald criteria
  • Education ≥ 8 ages
  • Italian mother language
  • Right-handedness
  • Use of corticosteroids for three months prior to the study, having and no acute exacerbations of symptoms within three months of the study.

Exclusion Criteria:

  • Existence of visual acuity and acoustic perception problems, to prevent performance of VRRS activities
  • Relapses next to the time of enrolment (3 months)
  • EDSS > 6.5.

Sites / Locations

  • Irccs Fondazione Don Carlo GnocchiRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Active Comparator

Experimental

Active Comparator

Arm Label

VRRS Khymeia

Usual care program

VRRS Khymeia plus active tDCS

VRRS Khymeia plus placebo tDCS

Arm Description

The group will receive a kit home-based (a tablet home, an exercise equipment, access to a daily individualized training program). The exercise program will be remotely charged by therapist on the patient's computer. Each patient's performed session will be reviewed remotely by the therapist.

The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.

The group will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training

The group will receive 5 sessions of an individualized home-based VRRS training combined with placebo tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training

Outcomes

Primary Outcome Measures

Change in measure of quality of life
Quality of life will be measured by 54-item Multiple Sclerosis Quality of Life (MSQOL-54) questionnaire There is no single overall score for the MSQOL-54. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores. In addition, there are 12 subscales: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. There are also two single-item measures: satisfaction with sexual function and change in health. Administration forms and scoring instructions can be downloaded (https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/MSQOL54_995.pdf ). Higher values represent a better outcome

Secondary Outcome Measures

Change in balance
Mini-Balance Evalutation System (mini-BES) Test
Change in gait
12-item Multiple Sclerosis Walking Scale
Change gross manual dexterity
Box and Block Test
Change in global cognitive status
Montreal Cognitive Assessment (MoCA) test
Change cognitive status
Symbol Digit Modalities Test (Form Brief Repeatable Battery of Neuropsychological Tests )
Change in fatigue
Fatigue Severity Scale A questionnaire with 9 items (questions) Grading of each FSS item ranges from 1 to 7, where 1 indicates strong disagreement and 7 strong agreement, and the final score represents the mean value of the 9 items Higher values represent a worse outcome
Change in Emotional Traits
The Regulatory Emotional Self-Efficacy (RESE) scale The RESE scale assesses self-efficacy in expressing positive emotions and self-efficacy in managing negative emotions. With this scale, participants rate (ranging from 1 [not well at all] to 5 [very well]) their capability to manage their emotional life. RESE scale consists of 12 items and are calculated 3 scores: 1) self-efficacy in expressing positive emotions (POS) score; 2)self-efficacy in managing negative emotions (NEG) score; 3)self-efficacy in managing despondency/distress (DES) score Higher values within each score represent a better outcome
Change in Behavioral (depression)
Beck Depression Inventory
Change in Behavioral (anxiety)
State-trait anxiety inventory

Full Information

First Posted
February 2, 2018
Last Updated
February 9, 2021
Sponsor
Fondazione Don Carlo Gnocchi Onlus
Collaborators
IRCCS Centro Neurolesi Bonino-Pulejo, Messina (IT), IRCCS Fondazione Istituto Neurologico Casimiro Mondino, Pavia (IT), IRCCS San Camillo, Venezia, Italy, IRCCS San Raffaele Roma, Istituti Clinici Scientifici Maugeri SpA
search

1. Study Identification

Unique Protocol Identification Number
NCT03444454
Brief Title
Telerehabilitation in Multiple Sclerosis
Official Title
The Italian Network of Telerehabilitation: Evaluation of Telerehabilitation System for Continuum of Care in Multiple Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Unknown status
Study Start Date
February 26, 2018 (Actual)
Primary Completion Date
December 31, 2018 (Actual)
Study Completion Date
January 31, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Fondazione Don Carlo Gnocchi Onlus
Collaborators
IRCCS Centro Neurolesi Bonino-Pulejo, Messina (IT), IRCCS Fondazione Istituto Neurologico Casimiro Mondino, Pavia (IT), IRCCS San Camillo, Venezia, Italy, IRCCS San Raffaele Roma, Istituti Clinici Scientifici Maugeri SpA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The main aim of the study is to evaluate the efficacy of the Virtual Reality Rehabilitation System (VRRS, Khymeia) compared to usual care treatment for patients with MS at home. The effects of the intervention on outcome variables will be assessed using a randomized controlled trial design with a comparison group receiving usual care training. The investigators will assess the effect of VRRS system on the quality of life, motor, and cognitive abilities. (Phase I) In the second phase of the present study we aim to evaluate the effects induced by the treatment of active (anodal) transcranial Direct Current Stimulation (tDCS) applied to the left dorsolateral prefrontal cortex (lDLPFC) combined with VRRS compared to placebo tDCS stimulation combined with VRRS. The effects of the intervention patient-relevant outcomes will be assessed using a randomized controlled trial design with four groups. The investigators will assess the effect of VRRS system on patient-relevant outcomes motor, cognitive and participation. (Phase II)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis
Keywords
Telerehabilitation, Virtual reality, Quality of life, transcranial Direct Current Stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
136 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
VRRS Khymeia
Arm Type
Experimental
Arm Description
The group will receive a kit home-based (a tablet home, an exercise equipment, access to a daily individualized training program). The exercise program will be remotely charged by therapist on the patient's computer. Each patient's performed session will be reviewed remotely by the therapist.
Arm Title
Usual care program
Arm Type
Active Comparator
Arm Description
The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
Arm Title
VRRS Khymeia plus active tDCS
Arm Type
Experimental
Arm Description
The group will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
Arm Title
VRRS Khymeia plus placebo tDCS
Arm Type
Active Comparator
Arm Description
The group will receive 5 sessions of an individualized home-based VRRS training combined with placebo tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training
Intervention Type
Behavioral
Intervention Name(s)
VRRS Khymeia
Intervention Description
Participants will receive an individualized exercise program set up by the therapist. The intervention applied to the experimental group will consist of 30 sessions of Khymeia VRRS training distributed in five sessions for week, each lasting 45 minutes. Each session is constructed by alternating physical with cognitive activities. The sessions will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
Intervention Type
Behavioral
Intervention Name(s)
Usual care program
Intervention Description
The usual care group will have written, home-based exercise program, provided to them at an initial face-to-face assessment.
Intervention Type
Behavioral
Intervention Name(s)
VRRS Khymeia plus active tDCS
Intervention Description
Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training. The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
Intervention Type
Behavioral
Intervention Name(s)
VRRS Khymeia plus placebo tDCS
Intervention Description
Participants will receive 5 sessions each lasting 45 minutes of an individualized home-based VRRS training combined with active (anodal) tDCS applied to the left dorsolateral prefrontal cortex over 1 week, followed by 5 weeks of home-based VRRS training. The sessions of VRRS will initially be tailored to the patient's baseline characteristics. Remotely, the therapist will then adjust the participant's exercise program as appropriate, by changing exercises, level of difficulty or number of repetitions.
Primary Outcome Measure Information:
Title
Change in measure of quality of life
Description
Quality of life will be measured by 54-item Multiple Sclerosis Quality of Life (MSQOL-54) questionnaire There is no single overall score for the MSQOL-54. Two summary scores - physical health and mental health - can be derived from a weighted combination of scale scores. In addition, there are 12 subscales: physical function, role limitations-physical, role limitations-emotional, pain, emotional well-being, energy, health perceptions, social function, cognitive function, health distress, overall quality of life, and sexual function. There are also two single-item measures: satisfaction with sexual function and change in health. Administration forms and scoring instructions can be downloaded (https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/MSQOL54_995.pdf ). Higher values represent a better outcome
Time Frame
Baseline up to 6 weeks and 6 months
Secondary Outcome Measure Information:
Title
Change in balance
Description
Mini-Balance Evalutation System (mini-BES) Test
Time Frame
Baseline up to 6 weeks and 6 months
Title
Change in gait
Description
12-item Multiple Sclerosis Walking Scale
Time Frame
Baseline up to 6 weeks and 6 months
Title
Change gross manual dexterity
Description
Box and Block Test
Time Frame
Baseline up to 6 weeks and 6 months
Title
Change in global cognitive status
Description
Montreal Cognitive Assessment (MoCA) test
Time Frame
Baseline up to 6 weeks and 6 months
Title
Change cognitive status
Description
Symbol Digit Modalities Test (Form Brief Repeatable Battery of Neuropsychological Tests )
Time Frame
Baseline up to 6 weeks and 6 months
Title
Change in fatigue
Description
Fatigue Severity Scale A questionnaire with 9 items (questions) Grading of each FSS item ranges from 1 to 7, where 1 indicates strong disagreement and 7 strong agreement, and the final score represents the mean value of the 9 items Higher values represent a worse outcome
Time Frame
Baseline up to 6 weeks and 6 months
Title
Change in Emotional Traits
Description
The Regulatory Emotional Self-Efficacy (RESE) scale The RESE scale assesses self-efficacy in expressing positive emotions and self-efficacy in managing negative emotions. With this scale, participants rate (ranging from 1 [not well at all] to 5 [very well]) their capability to manage their emotional life. RESE scale consists of 12 items and are calculated 3 scores: 1) self-efficacy in expressing positive emotions (POS) score; 2)self-efficacy in managing negative emotions (NEG) score; 3)self-efficacy in managing despondency/distress (DES) score Higher values within each score represent a better outcome
Time Frame
Baseline up to 6 weeks and 6 months
Title
Change in Behavioral (depression)
Description
Beck Depression Inventory
Time Frame
Baseline up to 6 weeks and 6 months
Title
Change in Behavioral (anxiety)
Description
State-trait anxiety inventory
Time Frame
Baseline up to 6 weeks and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Confirmed diagnosis of Multiple Sclerosis (RR and SP) based on McDonald criteria Education ≥ 8 ages Italian mother language Right-handedness Use of corticosteroids for three months prior to the study, having and no acute exacerbations of symptoms within three months of the study. Exclusion Criteria: Existence of visual acuity and acoustic perception problems, to prevent performance of VRRS activities Relapses next to the time of enrolment (3 months) EDSS > 6.5.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Francesca Baglio, MD
Phone
0240308069
Email
fbaglio@dongnocchi.it
First Name & Middle Initial & Last Name or Official Title & Degree
Laura Mendozzi, MD
Phone
0240308206
Email
lmendozzi@dongnocchi.it
Facility Information:
Facility Name
Irccs Fondazione Don Carlo Gnocchi
City
Milano
State/Province
MI
ZIP/Postal Code
20148
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Mendozzi, MD
Phone
0240308069
Email
lmendozzi@dongnocchi.it

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
31132909
Citation
Di Tella S, Pagliari C, Blasi V, Mendozzi L, Rovaris M, Baglio F. Integrated telerehabilitation approach in multiple sclerosis: A systematic review and meta-analysis. J Telemed Telecare. 2020 Aug-Sep;26(7-8):385-399. doi: 10.1177/1357633X19850381. Epub 2019 May 27.
Results Reference
background
PubMed Identifier
34851211
Citation
Pagliari C, Di Tella S, Jonsdottir J, Mendozzi L, Rovaris M, De Icco R, Milanesi T, Federico S, Agostini M, Goffredo M, Pellicciari L, Franceschini M, Cimino V, Bramanti P, Baglio F. Effects of home-based virtual reality telerehabilitation system in people with multiple sclerosis: A randomized controlled trial. J Telemed Telecare. 2021 Dec 1:1357633X211054839. doi: 10.1177/1357633X211054839. Online ahead of print.
Results Reference
derived

Learn more about this trial

Telerehabilitation in Multiple Sclerosis

We'll reach out to this number within 24 hrs